Belmont, CA, United States of America

Eric Labonte

USPTO Granted Patents = 16 

 

 

Average Co-Inventor Count = 8.5

ph-index = 5

Forward Citations = 35(Granted Patents)


Location History:

  • Redwood City, CA (US) (2014 - 2016)
  • Fremont, CA (US) (2019)
  • Belmont, CA (US) (2016 - 2021)

Company Filing History:


Years Active: 2014-2021

where 'Filed Patents' based on already Granted Patents

16 patents (USPTO):

Title: The Innovative Contributions of Eric Labonte

Introduction

Eric Labonte is a prominent inventor based in Belmont, California. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that inhibit phosphate transport. With a total of 16 patents to his name, Labonte's work has the potential to impact therapeutic approaches for various health conditions.

Latest Patents

Among his latest patents are the NHE3-binding compounds and methods for inhibiting phosphate transport. These patents provide innovative agents that have activity as phosphate transport inhibitors. Specifically, they include inhibitors of phosphate transport in the gastrointestinal tract and the kidneys, along with methods for their use as therapeutic or prophylactic agents.

Career Highlights

Eric Labonte is currently associated with Ardelyx, Inc., a company focused on developing innovative therapies for patients with gastrointestinal and kidney diseases. His work at Ardelyx has been instrumental in advancing the understanding and treatment of phosphate transport-related conditions.

Collaborations

Labonte has collaborated with notable colleagues, including Jeffrey William Jacobs and Dominique Charmot. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to the development of groundbreaking solutions in the pharmaceutical industry.

Conclusion

Eric Labonte's contributions to the field of pharmaceutical sciences through his patents and collaborations highlight his role as a key innovator. His work continues to pave the way for advancements in therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…